An Osaka University-led research team has recently published findings that provide a ray of hope for the millions of Parkinson’s disease (PD) sufferers worldwide. Although more common in those aged over sixty, PD can strike at any age, with an estimated prevalence of 41 per 100,000 people in their forties. And while not fatal in and of itself, the progressive neurodegeneration that is characteristic of PD can often cause secondary effects that lead to death.
The exact cause of PD is still a mystery, but researchers believe that both genetics and the environment are likely to play a part. Importantly though, all PD patients show a loss of dopaminergic neurons in the brain and increased levels of a protein called ?-synuclein, which accumulates in Lewy bodies. Lewy bodies are a pathological feature of both familial and sporadic forms of the disease, as well as some types of dementia.
In the study published this month in Scientific Reports, the team led by researchers from Osaka University’s Graduate School of Medicine focused on ?-synuclein as a target for a novel PD treatment.
“Although there are drugs that treat the symptoms associated with PD, there is no fundamental treatment to control the onset and progression of the disease,” explains lead author Takuya Uehara. “Therefore, we looked at ways to prevent the expression of ?-synuclein and effectively eliminate the physiological cause of PD.”
To do this, the researchers designed short fragments of DNA that are mirror images of sections of the ?-synuclein gene product. The constructs were stabilized by the addition of amido-bridging. The resulting fragments, called amido-bridged nucleic acid-modified antisense oligonucleotides (ASOs), bind to their matching mRNA sequence, preventing it from being translated into protein. After screening 50 different ASOs, the researchers settled on a 15-nucleotide sequence that decreased ?-synuclein mRNA levels by 81%.
“When we tested the ASO in a mouse model of PD, we found that it was delivered to the brain without the need for chemical carriers,” says co-lead author Chi-Jing Choong. “Further testing showed that the ASO effectively decreased ?-synuclein production in the mice and significantly reduced the severity of disease symptoms within 27 days of administration.”
Explains senior author of the study Hideki Mochizuki, “Our results showed that gene therapy using ?-synuclein-targeting ASOs is a promising strategy for the control and prevention of PD. We expect that in the future, this method will be used to not only successfully treat PD, but also dementia caused by ?-synuclein accumulation.”
Learn more: Stopping Parkinson’s disease before it starts
The Latest on: Parkinson’s disease
via Google News
The Latest on: Parkinson’s disease
- Vercise Genus Deep Brain Stimulation for Parkinson’s FDA Approvedon January 25, 2021 at 10:05 am
Boston Scientific has landed FDA clearance for its Vercise Genus Deep Brain Stimulation (DBS) System. This is the fourth generation of the company's ...
- Parkinson’s disease: The nine lesser-known warning signs found in the mouthon January 25, 2021 at 9:06 am
PARKINSON'S disease is a condition whereby parts of the brain become progressively damaged over many years. It is commonly associated with movement problems, but the condition can be signalled in ...
- World Parkinson Coalition® Launches Research Spotlight Serieson January 25, 2021 at 7:15 am
The World Parkinson Coalition (WPC) is launching its first ever WPC Research Spotlight series. This engaging series will include six interviews in 2021 with renowned Parkinson scientists, inviting ...
- FDA approves Boston Scientific's newest deep brain stimulator for Parkinson's diseaseon January 25, 2021 at 5:01 am
Boston Scientific has obtained approval from the FDA for the fourth generation of its Vercise Genus deep brain stimulation system, allowing conditional use while within an MRI scanner.
- Million-pound boost for Edinburgh medical tech firm behind digital Parkinson’s disease penon January 25, 2021 at 4:30 am
An Edinburgh medical technology company has secured a seven-figure financial injection to support the launch of a “digital pen” that can provide an early warning of Parkinson’s disease.
- Focused ultrasound subthalamotomy revealed improvement in Parkinson’s patientson January 24, 2021 at 12:12 pm
In patients suffering from Parkinson's disease displaying signs of motor dysfunction even after receiving treatment, this randomized control trial revealed improvement in motor features, such ...
- Parkinson’s meds are hard to grab, so TikTok users crowdsourced a solutionon January 23, 2021 at 6:00 am
That video set off a domino effect, inspiring designers, engineers, and hobbyists across TikTok to craft a better pill bottle for people with tremors or other motor disorders. The video made its way ...
- After Parkinson’s diagnosis, guitarist learns to play againon January 23, 2021 at 12:12 am
The Norfolk guitarist marked the end of 2020 by playing a three-hour set at Black Cow Fat Pig, his first performance in front of a crowd in about a year. “There’s always a little bit of nerves when ...
- Parkinson Hasler named BYU women’s tennis head coachon January 22, 2021 at 4:00 pm
BYU director of athletics Tom Holmoe announced today the hiring of Holly Parkinson Hasler as the new head coach of the women’s tennis program. Parkinson Hasler first came to BYU in 1997 out of Houston ...
- TikTok Users Rallied to Design a Better Pill Bottle for People With Parkinson’son January 22, 2021 at 9:00 am
TikTok users have rallied to 3D-print better pill bottles that are easily usable by people with shaky hands, such as those with Parkison's.
via Bing News